atrasentan has been researched along with Body Weight in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awni, WM; J Brennan, J; Klein, CE; L Andress, D; Lin, CW; Mostafa, NM | 1 |
| de Zeeuw, D; Heerspink, HJL; Koomen, JV; Mostafa, NM; Parving, HH; Stevens, J | 1 |
| Harris, NR; Leskova, W; Wang, Z; Yadav, AS | 1 |
| Best, PJ; Bonetti, PO; Holmes, DR; Lerman, A; Lerman, LO; Rodriguez-Porcel, M | 1 |
| da Silva, AA; Hall, JE; Kuo, JJ; Tallam, LS | 1 |
| Eshiro, K; Matsumura, Y; Nishida, M; Okada, Y; Takaoka, M | 1 |
| Allan, A; Brown, L; Fenning, A; Hoey, A; Levick, S | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Opocensky, M; Vanêcková, I; Vernerová, Z | 1 |
| Berthiaume, N; Carlson, CJ; Rondinone, CM; Zinker, BA | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Bianciotti, LG; De Bold, AJ | 1 |
| Derebail, VK; Pollock, DM; Pollock, JS; Yamamoto, T | 1 |
1 trial(s) available for atrasentan and Body Weight
| Article | Year |
|---|---|
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Biological Variation, Population; Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Metabolic Clearance Rate; Renal Elimination; Renal Insufficiency; Severity of Illness Index; Sodium | 2018 |
11 other study(ies) available for atrasentan and Body Weight
| Article | Year |
|---|---|
Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.
Topics: Aged; Albuminuria; Atrasentan; Body Weight; Clinical Trials, Phase II as Topic; Creatinine; Diabetic Nephropathies; Double-Blind Method; Edema; Female; Humans; Kidney Function Tests; Male; Middle Aged; Randomized Controlled Trials as Topic | 2018 |
Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan.
Topics: Administration, Oral; Animals; Atrasentan; Blood Flow Velocity; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin A Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique, Indirect; Male; Mice; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Pyrrolidines; Regional Blood Flow; Retinal Vessels | 2010 |
Endothelin type A receptor antagonism restores myocardial perfusion response to adenosine in experimental hypercholesterolemia.
Topics: Adenosine; Animals; Atrasentan; Body Weight; Capillary Permeability; Cholesterol, Dietary; Coronary Circulation; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hemodynamics; Hypercholesterolemia; Lipids; Microcirculation; Protein Isoforms; Pyrrolidines; Swine | 2003 |
Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension.
Topics: Adipose Tissue; Animals; Atrasentan; Blood Pressure; Body Weight; Eating; Endothelin A Receptor Antagonists; Endothelin-1; Fats; Heart Rate; Hormones; Hypertension; Kidney; Male; Obesity; Pyrrolidines; Rats; Rats, Sprague-Dawley; Viscera | 2004 |
Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Body Mass Index; Body Weight; Cardiomegaly; Drug Administration Schedule; Drug Therapy, Combination; Heart; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Injections, Subcutaneous; Intubation, Gastrointestinal; Lung; Male; Monocrotaline; Organ Size; Pulmonary Artery; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Time Factors; Tunica Media; Ventricular Pressure | 2004 |
Reversal of cardiac dysfunction by selective ET-A receptor antagonism.
Topics: Acetylcholine; Action Potentials; Animals; Aorta, Thoracic; Atrasentan; Body Weight; Collagen; Desoxycorticosterone; Disease Models, Animal; Drinking; Endothelin A Receptor Antagonists; Hypertension; Hypertrophy, Left Ventricular; In Vitro Techniques; Male; Myocardial Contraction; Nephrectomy; Norepinephrine; Papillary Muscles; Potassium Chloride; Pyrrolidines; Rats; Rats, Wistar; Ventricular Remodeling | 2005 |
Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin A Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heart Ventricles; Hypertension; Kidney; Male; Myocardium; Organ Size; Osmolar Concentration; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Sodium Chloride, Dietary; Sulfonamides; Survival Analysis | 2005 |
Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats.
Topics: Animals; Atrasentan; Blood Pressure; Body Weight; Drinking; Endothelin-1; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Muscle, Skeletal; Obesity; Pyrrolidines; Rats; Rats, Zucker; Signal Transduction | 2005 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
Effect of selective ET(A) receptor blockade on natriuretic peptide gene expression in DOCA-salt hypertension.
Topics: Animals; Atrasentan; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Desoxycorticosterone; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart; Heart Ventricles; Hypertension; Male; Myocardium; Myosin Heavy Chains; Natriuretic Peptide, Brain; Organ Size; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium, Dietary; Transcription, Genetic | 2000 |
Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; Desoxycorticosterone; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Kidney; Male; Natriuresis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 2000 |